about
Serum CXCL16 as a novel marker of renal injury in type 2 diabetes mellitusAllelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long-Term Carrier State in the StallionScavenger receptor structure and function in health and disease.The function of the chemokine receptor CXCR6 in the T cell response of mice against Listeria monocytogenes.Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling.Standardizing scavenger receptor nomenclatureFunction modification of SR-PSOX by point mutations of basic amino acids.Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathwayThe perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgeryChanges in chondrocyte gene expression following in vitro impaction of porcine articular cartilage in an impact injury model.Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal DiseaseElevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke.Ceramide in the regulation of eryptosis, the suicidal erythrocyte death.CXC chemokine ligand 16 is increased in gestational diabetes mellitus and preeclampsia and associated with lipoproteins in gestational diabetes mellitus at 5 years follow-up.A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease.
P2860
Q28539322-F462DFCE-4FD1-43EC-9768-25894B288AE3Q28588626-4A2D4799-E089-4963-93E1-0CCBB54FB764Q30958610-C64B38F2-CEAF-4F5E-AEF6-2DF465CBCA58Q33618442-F9CA0361-5E1F-401F-ABF7-60D3C5649442Q33869955-1DC6AC6B-36A8-4063-B7A4-AB12F30F75AEQ34406276-92E2D363-565E-4927-BFF1-C56EDBA68CB7Q35009160-B7B18428-A5D5-4174-BF2A-9D50C412A2EBQ35224401-F32AC381-2930-4857-9F09-A09AB09BC611Q36476906-DB97ACF6-1FA1-4998-8BBB-9581A9C6FB97Q36557037-D49859E8-645B-444A-A6D1-9F49180F1B7BQ37428143-2CE8183F-D4A1-4D9C-A374-D92115F9F488Q37636842-E65FD1A0-9C19-47B2-AFBF-17D8B5DDB6E4Q38338337-10311F88-803E-4051-B1A0-543DE3A5B5A7Q40073242-57A1137B-9D09-4228-A853-A7987FF9D00AQ40220899-36D9CCD8-39FF-4AA6-86CE-831138A4C0E9
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@ast
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@en
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@nl
type
label
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@ast
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@en
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@nl
prefLabel
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@ast
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@en
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@nl
P1433
P1476
CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?
@en
P2093
Allan Sirsjö
Yuri Sheikine
P304
P356
10.1016/J.ATHEROSCLEROSIS.2007.11.034
P577
2008-01-14T00:00:00Z